JP7642611B2 - 放射線曝露を処置するためのセピアプテリン及びその代謝産物の使用 - Google Patents

放射線曝露を処置するためのセピアプテリン及びその代謝産物の使用 Download PDF

Info

Publication number
JP7642611B2
JP7642611B2 JP2022507561A JP2022507561A JP7642611B2 JP 7642611 B2 JP7642611 B2 JP 7642611B2 JP 2022507561 A JP2022507561 A JP 2022507561A JP 2022507561 A JP2022507561 A JP 2022507561A JP 7642611 B2 JP7642611 B2 JP 7642611B2
Authority
JP
Japan
Prior art keywords
mir
composition
subject
radiation
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022507561A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022543655A (ja
JP2022543655A5 (https=
JPWO2021026247A5 (https=
Inventor
メザロマ，エレオノーラ
ラベンダー，クリストファー
ミケルセン，ロス
ヤコブレフ，ヴァシリー
スミス，ニール
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Virginia Commonwealth University
Original Assignee
Virginia Commonwealth University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Virginia Commonwealth University filed Critical Virginia Commonwealth University
Publication of JP2022543655A publication Critical patent/JP2022543655A/ja
Publication of JP2022543655A5 publication Critical patent/JP2022543655A5/ja
Publication of JPWO2021026247A5 publication Critical patent/JPWO2021026247A5/ja
Priority to JP2025029508A priority Critical patent/JP2025098011A/ja
Application granted granted Critical
Publication of JP7642611B2 publication Critical patent/JP7642611B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
JP2022507561A 2019-08-05 2020-08-05 放射線曝露を処置するためのセピアプテリン及びその代謝産物の使用 Active JP7642611B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025029508A JP2025098011A (ja) 2019-08-05 2025-02-26 放射線曝露を処置するためのセピアプテリン及びその代謝産物の使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962882937P 2019-08-05 2019-08-05
US62/882,937 2019-08-05
PCT/US2020/045026 WO2021026247A1 (en) 2019-08-05 2020-08-05 Use of sepiapterin and metabolites thereof to treat radiation exposure

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025029508A Division JP2025098011A (ja) 2019-08-05 2025-02-26 放射線曝露を処置するためのセピアプテリン及びその代謝産物の使用

Publications (4)

Publication Number Publication Date
JP2022543655A JP2022543655A (ja) 2022-10-13
JP2022543655A5 JP2022543655A5 (https=) 2023-08-15
JPWO2021026247A5 JPWO2021026247A5 (https=) 2023-08-15
JP7642611B2 true JP7642611B2 (ja) 2025-03-10

Family

ID=72148243

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022507561A Active JP7642611B2 (ja) 2019-08-05 2020-08-05 放射線曝露を処置するためのセピアプテリン及びその代謝産物の使用
JP2025029508A Pending JP2025098011A (ja) 2019-08-05 2025-02-26 放射線曝露を処置するためのセピアプテリン及びその代謝産物の使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025029508A Pending JP2025098011A (ja) 2019-08-05 2025-02-26 放射線曝露を処置するためのセピアプテリン及びその代謝産物の使用

Country Status (21)

Country Link
US (1) US20220273661A1 (https=)
EP (2) EP4454712A3 (https=)
JP (2) JP7642611B2 (https=)
CN (2) CN119837879A (https=)
AU (1) AU2020324435B2 (https=)
BR (1) BR112022002029A2 (https=)
CA (1) CA3146477A1 (https=)
DK (1) DK4009978T3 (https=)
ES (1) ES2994060T3 (https=)
FI (1) FI4009978T3 (https=)
HR (1) HRP20241653T1 (https=)
HU (1) HUE069012T2 (https=)
IL (1) IL290321B1 (https=)
LT (1) LT4009978T (https=)
MX (1) MX2022001535A (https=)
PL (1) PL4009978T3 (https=)
PT (1) PT4009978T (https=)
RS (1) RS66096B1 (https=)
SI (1) SI4009978T1 (https=)
SM (1) SMT202500089T1 (https=)
WO (1) WO2021026247A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025098011A (ja) * 2019-08-05 2025-07-01 ピーティーシー セラピューティクス エムピー，インコーポレイテッド 放射線曝露を処置するためのセピアプテリン及びその代謝産物の使用

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11072614B2 (en) 2016-11-29 2021-07-27 Ptc Therapeutics Mp, Inc. Polymorphs of sepiapterin and salts thereof
US11130760B2 (en) 2016-11-29 2021-09-28 Ptc Therapeutics Mp, Inc. Polymorphic form of sepiapterin
JP7811085B2 (ja) 2017-09-01 2026-02-04 ピーティーシー セラピューティクス エムピー，インコーポレイテッド セピアプテリンを含む医薬組成物及びその使用
EP3801536B1 (en) 2018-05-30 2024-07-17 PTC Therapeutics MP, Inc. Administration of sepiapterin without food for use in a method for increasing sepiapterin plasma exposure
CN112654356A (zh) 2018-05-30 2021-04-13 Ptc医疗Mp公司 增加四氢生物蝶呤血浆暴露的组合物和方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007511520A (ja) 2003-11-13 2007-05-10 ザ ジェネラル ホスピタル コーポレーション 疼痛を治療するための方法
JP2008520574A (ja) 2004-11-17 2008-06-19 バイオマリン ファーマシューティカル インコーポレイテッド テトラヒドロビオプテリンの安定性錠剤処方物
JP2016530333A (ja) 2013-09-13 2016-09-29 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ アーカンソー 放射線の影響から防護するため及び放射線の影響を緩和するための組成物の調製及び使用
JP2017530159A (ja) 2014-10-02 2017-10-12 サイトソーベンツ・コーポレーション 放射線で誘発された粘膜炎、食道炎、小腸炎、大腸炎、及び胃腸管急性放射線症候群を予防又は治療するための胃腸管投与多孔質消化管吸着剤ポリマーの使用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5910304A (en) 1982-12-13 1999-06-08 Texas A&M University System Low-dose oral administration of interferons
CA1320905C (en) 1986-11-06 1993-08-03 Joseph M. Cummins Treatment of immuno-resistant disease
US6036949A (en) 1998-03-05 2000-03-14 Amarillo Biosciences, Inc. Treatment of fibromyalgia with low doses of interferon
TWI359019B (en) * 2006-08-14 2012-03-01 Merck Eprova Ag Use of folates for the prevention and treatment of
US11130760B2 (en) 2016-11-29 2021-09-28 Ptc Therapeutics Mp, Inc. Polymorphic form of sepiapterin
US11072614B2 (en) 2016-11-29 2021-07-27 Ptc Therapeutics Mp, Inc. Polymorphs of sepiapterin and salts thereof
JP7811085B2 (ja) 2017-09-01 2026-02-04 ピーティーシー セラピューティクス エムピー，インコーポレイテッド セピアプテリンを含む医薬組成物及びその使用
AU2019277372B2 (en) 2018-05-30 2024-12-19 Ptc Therapeutics Mp, Inc. Pharmaceutically acceptable salts of sepiapterin
IL290321B1 (en) * 2019-08-05 2026-04-01 Ptc Therapeutics Inc Use of spiapterin and its metabolites for radiation exposure treatment
CN110354133A (zh) * 2019-08-26 2019-10-22 鞍山市肿瘤医院 四氢生物蝶呤的应用及药物

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007511520A (ja) 2003-11-13 2007-05-10 ザ ジェネラル ホスピタル コーポレーション 疼痛を治療するための方法
JP2008520574A (ja) 2004-11-17 2008-06-19 バイオマリン ファーマシューティカル インコーポレイテッド テトラヒドロビオプテリンの安定性錠剤処方物
JP2016530333A (ja) 2013-09-13 2016-09-29 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ アーカンソー 放射線の影響から防護するため及び放射線の影響を緩和するための組成物の調製及び使用
JP2017530159A (ja) 2014-10-02 2017-10-12 サイトソーベンツ・コーポレーション 放射線で誘発された粘膜炎、食道炎、小腸炎、大腸炎、及び胃腸管急性放射線症候群を予防又は治療するための胃腸管投与多孔質消化管吸着剤ポリマーの使用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Chin med J，2016年，129:2733-2740
Curr Drug Targets，2010年，11:1366-1374

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025098011A (ja) * 2019-08-05 2025-07-01 ピーティーシー セラピューティクス エムピー，インコーポレイテッド 放射線曝露を処置するためのセピアプテリン及びその代謝産物の使用

Also Published As

Publication number Publication date
AU2020324435B2 (en) 2026-03-19
IL290321B1 (en) 2026-04-01
PT4009978T (pt) 2024-11-05
RS66096B1 (sr) 2024-11-29
CA3146477A1 (en) 2021-02-11
EP4009978B1 (en) 2024-09-25
EP4454712A2 (en) 2024-10-30
EP4454712A3 (en) 2025-01-01
SMT202500089T1 (it) 2025-03-12
IL290321A (en) 2022-04-01
CN119837879A (zh) 2025-04-18
MX2022001535A (es) 2022-03-04
PL4009978T3 (pl) 2025-02-24
JP2022543655A (ja) 2022-10-13
FI4009978T3 (fi) 2024-11-01
ES2994060T3 (en) 2025-01-16
AU2020324435A1 (en) 2022-02-24
DK4009978T3 (da) 2024-10-14
US20220273661A1 (en) 2022-09-01
WO2021026247A1 (en) 2021-02-11
LT4009978T (lt) 2024-11-25
HRP20241653T1 (hr) 2025-04-25
JP2025098011A (ja) 2025-07-01
BR112022002029A2 (pt) 2022-06-07
HUE069012T2 (hu) 2025-02-28
SI4009978T1 (sl) 2025-03-31
CN114555090A (zh) 2022-05-27
EP4009978A1 (en) 2022-06-15
CN114555090B (zh) 2024-12-17

Similar Documents

Publication Publication Date Title
JP7642611B2 (ja) 放射線曝露を処置するためのセピアプテリン及びその代謝産物の使用
EP3054952B1 (en) Combinations of histone deacetylase 6 inhibitors and the her2 inhibitor lapatinib for use in the treatment of breast cancer
Wang et al. The roles of oxidative stress and Beclin-1 in the autophagosome clearance impairment triggered by cardiac arrest
JP2018507244A (ja) 肺線維症の治療のためのアンギオテンシンｉｉ受容体作動薬
US20090318534A1 (en) Methods and compositions for the treatment of skin diseases and disorders
CN115605201A (zh) 血管紧张素ii 2型受体激动剂的新用途
EP2512468B1 (en) METHOD OF TREATING SCARS AND ß-CATENIN-MEDIATED DISORDERS USING NEFOPAM COMPOUNDS
US20200147050A1 (en) Biphenyl sulfonamide compounds for the treatment of type iv collagen diseases
JP7285001B2 (ja) サフラナール製剤による肝臓癌治療の方法
US20220257626A1 (en) Treatment comprising sglt inhibitors
HK40118407A (en) Use of sepiapterin and metabolites thereof to treat radiation exposure
EA052521B1 (ru) Применение сепиаптерина и его метаболитов для лечения радиационного облучения
EA048135B1 (ru) Применение сепиаптерина и его метаболитов для лечения радиационного облучения
HK40075560A (en) Use of sepiapterin and metabolites thereof to treat radiation exposure
HK40075560B (en) Use of sepiapterin and metabolites thereof to treat radiation exposure
US20190365689A1 (en) Use of ape/ref-1 redox specific inhibitors for treating metastatic prostate cancer
CN111166756B (zh) 20（S）-人参皂苷-Rg3在逆转胶质瘤细胞对化疗药物的耐药性中的用途
US10517842B2 (en) Methods of modulating miRNA levels and compositions for use in the same
JP7525591B2 (ja) 心機能不全を予測及び処置するための方法
EP4545076A1 (en) Lat1 selective inhibitors for use in the treatment of adverse ventricular -remodelling and of heart failure
CN116492342B (zh) 氯喹或羟氯喹在制备治疗尼洛替尼肾脏毒副作用药物中的应用
JP7854389B2 (ja) Ｋｌｋ５／７デュアル阻害剤としてのベンゾキサジノン化合物
CN119745887A (zh) 小分子激动剂tepp-46在制备预防和/或治疗主动脉瘤及相关心血管疾病的药物中的应用
TW202415366A (zh) 異硫氰酸酯結構修飾化合物於預防或治療肝臟疾病之用途
JP2020132626A (ja) サフラナール製剤によるｃｄｃ２５ｂの抑制および阻害

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230804

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230804

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240626

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240709

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241009

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250128

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250226

R150 Certificate of patent or registration of utility model

Ref document number: 7642611

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150